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CObjective: To summarize the clinical experiences and mid-term follow-up results of perventricular closure of
perimembranous ventricular septal defect without cardiopulmonary bypass under transesophageal echocardiog-
raphy guidance.
Methods: A total of 408 patients with perimembranous ventricular septal defects, aged 5 months to 15 years
(3.1  1.7 years) with a body weight of 4.5 to 26 kg (13.6  5.5 kg), underwent perventricular device closure.
The procedure was performed via a small lower sternal incision. A guidewire was inserted through the ventricular
septal defect to the left ventricle under transesophageal echocardiography guidance after a pursestring suture was
placed on the right ventricular free wall. A modified delivery sheath was introduced over the guidewire to estab-
lish the delivery pathway. Proper devices were delivered and then deployed if no atrioventricular or aortic valvu-
lar disturbance, or residual shunt was detected by transesophageal echocardiography. Patients were followed up
with a standard protocol, which is once every month in the first 3 postoperative months and then once every
3 months with echocardiography, electrocardiography, and chest radiography in each follow-up.
Results: A total of 393 patients in this group underwent successful closure (96.3%), and the procedure was con-
verted to conventional open repair in 15 patients (3.7%). A total of 213 symmetric devices (54.2%) and 180
asymmetric devices (45.8%) were implanted. Only 6 of the 393 patients (3.5%) received transfusion of blood
products. New trivial or mild tricuspid regurgitation was found in 13 patients (3.3%), and there was no worsening
of regurgitation in those patients with existing tricuspid regurgitation before operation. Eleven patients (2.8%)
had incomplete right bundle branch block. Most of the patients were discharged 3 to 5 days after the operation.
Follow-up in all patients ranged from 3months to 2 years (14.6 6.2 months) and revealed no residual shunt, new
or aggravating aortic regurgitation, obstruction of left or right ventricular outflow tract, or device dislocation.
Conclusion:Minimally invasive perventricular device closure of ventricular septal defect without cardiopulmo-
nary bypass is a simple, effective, and relatively safe intervention under guidance of transesophageal echocardi-
ography. This method should be considered for patients with ventricular septal defect. Long-term follow-up is
necessary. (J Thorac Cardiovasc Surg 2010;139:1409-15)Perventricular device closure (PVDC) of ventricular septal
defect (VSD) without cardiopulmonary bypass (CPB) under
transesophageal echocardiography (TEE) guidance is in-
creasingly being used.1-5 In 2007, Xing and colleagues6 re-
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The Journal of Thoracic and Carseptal defect (PMVSD) with a newly designed delivery sys-
tem using this technique. Subsequently, this new technique
has been widely used in China.6-13 According to the device
manufacturer (Shanghai Xingzhuangjiyi Alloy Material
Corp, Shanghai, China), more than 1000 cases of PVDC
were performed between March 2007 and April 2009. We
retrospectively reviewed 408 patients in the 5 heart centers
pioneering this new intervention technique and summarized
the mid-term results.PATIENTS AND METHODS
Case Data
Between March 2007 and April 2009, 408 patients with isolated
PMVSD, aged 5 months to 15 years (3.1  1.7 years) with a body weight
of 4.5 to 26 kg (13.6 5.5 kg), underwent minimally invasive PVDC under
TEE guidance.
Patients were enrolled in our program for the following indications: re-
peated respiratory infection (>6 times per year); slow body development;
heart enlargement observed on chest x-ray; left atrium enlargement ob-
served on echocardiography (left atrium/aorta ratio > 1.5); and leftdiovascular Surgery c Volume 139, Number 6 1409
Abbreviations and Acronyms
AVB ¼ atrioventricular block
CPB ¼ cardiopulmonary bypass
LV ¼ left ventricle
PMVSD ¼ perimembranous ventricular septal
defect
PVDC ¼ perventricular device closure
RV ¼ right ventricle
TEE ¼ transesophageal echocardiography
VSD ¼ ventricular septal defect
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Dventricular (LV) enlargement observed on echocardiography (LV end-
diastolic diameter>2 standard deviations). The following patients were ex-
cluded: those with nonrestrictive or malaligned VSDs, those with VSDs
with significant aortic prolapse, newborn or young infants with a large
VSD and pulmonary hypertension, and patients who could not be followed.
Among our group, 213 (52.2%) were boys. A total of 129 patients
(31.6%) in this group were excluded from transcatheter closure by cardiol-
ogists for different reasons, such as relatively large VSD dimension com-
pared with low body weight or close proximity to the aortic valve. VSD
size, measured by 2-dimensional transthoracic echocardiography, ranged
from 3 to 12mm (5.3 1.6 mm). TEEwas performed before device implan-
tation to determine the shape and size of the VSD, and adjacent structures.
An informed consent was signed by each family before operation. This tech-
nique was approved by the institutional review board.Devices and Delivery System
The Occluder (No. 20043770007) used in this cohort was a modified form
derived from the Amplatzer (AGAMedical Corp, Plymouth, MN) VSD clo-
sure device and was designed and manufactured by Shanghai Xingzhuang-
jiyi Alloy Material Corporation. Two types of occluders were supplied:
concentric (symmetric) and eccentric (asymmetric) (Figure 1). The device
consisted of a short waist, a left disk, and a right disk. The device size was
chosen according to the diameter of the VSD. We recommended a device
with a waist size 1 to 2 mm larger than the VSD diameter, an eccentric oc-
cluder for patients with a VSD margin less than 2 mm from the aortic valve,
and a concentric occluder for other types of VSDs.
The total length of the device ranged from 10 to 20 cm. The entire deliv-
ery system was modified by Dr Xing and consisted of an 18G trocar, a flex-
ible guidewire, a dilator, a delivery sheath, and a loading sheath (Figure 2).
The occluder (with a screw nut on it) was connected to the delivery cable
(with a screw bolt on it) after rotating clockwise and then retracted into
the loading sheath. After the delivery sheath was passed through the
VSD, the occluder was advanced across the VSD and rotated counterclock-
wise to release the occluder.
Procedure
Patients were placed in a supine position under general anesthesia. The
TEE probe was inserted. A 3- to 4-cm incision was made in the inferior ster-
num, and a pericardiotomy was performed. The free right ventricular (RV)
surface was exposed. To determine the puncture site, the RV free wall was
slightly palpated to locate the area of maximal thrill corresponding to the
VSD location. A pursestring suture was placed at this location. The free
wall was puncturedwithin the suture using a trocar, the needle was removed,
and a hyperechogenic guidewire was inserted. The guidewire was advanced
through the RV cavity, slowly advanced toward the shunt orifice in the RV
under TEE guidance, and then advanced across the VSD to the LV cavity.
An imaging plane was selected to clearly view the RV orifice and guidewire.1410 The Journal of Thoracic and Cardiovascular SurA modified delivery sheath was introduced over the guidewire to the LV,
establishing the delivery pathway. The occluder was advanced along the
sheath and released after confirmed by TEE, as previously described.6-12
We reiterate that 2 tips should be used to ensure that the eccentric
occluder is released in an appropriate position, particularly in patients in
whom the VSD is close to the aortic valve. First, a special mark is made
on the loading sheath after the device is retracted in the loading sheath to
indicate the flat surface of the eccentric occluder. Second, the operator can
adjust the device by the platinum mark (on the eccentric side of the left
disk) to make the hyperechogenic platinum mark rightly deviate from the
aortic valve and face the heart apex (Figures 3–7). This maneuver ensures
correct and easy delivery of the occluder. The device can be easily
retracted and redeployed in case of inappropriate position of the occluder
causing valvular regurgitation or LV or RV outflow tract obstruction.
When necessary, another puncture site on the RV free wall can be chosen.
In our group, 11 patients (2.7%) had multiple RV punctures.RESULTS
Intraoperative and Early Postoperative Period
A total of 393 patients (96.3%) in this cohort underwent
perventricular closure of VSDs, and the procedure was con-
verted to conventional open repair in the remaining 15 pa-
tients (3.7%). Of the successful PVDC cases, symmetric
devices were implanted in 213 patients (54.2%) and asym-
metric devices were implanted in the remaining patients. A
total of 387 patients (96.5%) did not require transfusion of
blood products.
New trivial or mild tricuspid regurgitation was detected in
13 patients (3.3%) by intraoperative TEE. None of the pa-
tients had more than a mild degree of regurgitation, and no
worsening regurgitation was observed in those with existing
tricuspid regurgitation before surgery. No obvious residual
shunt or aortic regurgitation was detected.
Incomplete right bundle branch block was found in 11 pa-
tients (2.8%). Transient complete atrioventricular block
(AVB) was observed in 3 patients at postoperative days 3
(2 patients) and 4 (1 patient) before discharge. All of these
patients regained sinus rhythm after a 3- to 5-day short
course of corticosteroid therapy. None of these patients re-
quired temporary or permanent pacemaker implantation.
One pericardial effusion occurred 4 days after operation
and required repeated pericardial drainage.
The total operative time was less than 90 minutes, and the
time for device implantation ranged from 5 to 60 minutes
(17.8  8.7 minutes). All patients were extubated within 2
hours after the operation. In recent operations, we have be-
gun to extubate patients on the table. Almost all patients
were discharged 3 to 5 days after operation.Conversion to Conventional Open Repair With
Cardiopulmonary Bypass in 15 Patients
Aortic insufficiency from aortic prolapse occurred in 5 pa-
tients. Moderate aortic insufficiency occurred in 3 patients
after the left disk was released, and aortic insufficiency oc-
curred immediately after the delivery sheath was inserted
in the LV cavity in 2 patients. The undetected aortic cuspgery c June 2010
FIGURE 1. Concentric occluder (left) and eccentric occluder (right).
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Dprolapse was confirmed in all 5 patients during open repair.
Aortic insufficiency remained mild after open surgery.
Three patients had residual shunts. The interventricular
shunt remained after the complete release of disks. During
open surgery, membranous aneurysms and multiple open-
ings in the right side were found in all 3 patients. There
was a discrepancy of preoperative TEE findings and intrao-
perative findings leading to inadequate assessment.
Two patients had RV outflow tract obstruction. A new
pressure gradient of 20 to 40 mm Hg in the RV outflow tractFIGURE 2. Delivery system: A, 18G trocar. B, Guidewire. C, Dilator and
delivery sheath. D, Loading sheath with an eccentric occluder.
The Journal of Thoracic and Carwas detected by TEE after device deployment. Systolic
thrills could be felt on the surface of the RV free wall along
the RV outflow tract. Abnormal hypertrophic muscle bun-
dles were found pushing into the ventricular cavity by the
disk, resulting in stenosis of the outflow tract.
The guidewire failed to cross the VSD in 2 patients.
Despite repeated guidewire attempts and different puncture
sites, the guidewire failed to pass through the VSD. Direct
visual examination of VSDs revealed the puncture points;
the VSD opening on the LV side and the VSD aneurysmal
opening on the RV side were not in the same axis.
Abnormal occluder plasticity was found in 2 patients. In 1
patient, although there was no residual interventricular
shunt, a wide range of occluder motion was observed. We
chose open repair out of concern that the device might be-
come loose in the future. We found the wide range of motion
was caused by the weak and friable wall of the membranous
aneurysm. Device distortion was found in 1 patient because
the device was too big and crowded in the tunnel-like mem-
branous aneurysm.
Severe arrhythmia occurred in 1 patient immediately after
the guidewire passed through and touched the PMVSD tis-
sues. The arrhythmia stopped spontaneously after removal
of the guidewire. However, arrhythmia recurred duringFIGURE 3. Long-axis view of VSD from TEE (almost no rim between
VSD and aortic valve).
diovascular Surgery c Volume 139, Number 6 1411
FIGURE 4. Guidewire through VSD.
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Dsubsequent attempts, an open surgery was performed. Sinus
rhythm was regained after releasing the aortic clamp. It re-
mains unknown why the heart reacted in this manner.
Follow-ups
There is a standard protocol for following up these
patients. Patients were asked to return once per month in
the first 3 months and then once every 3 months. Echocardi-
ography to detect the position of the occluder, tricuspid and
aortic valvular motions, and residual shunt; electrocardiog-
raphy to detect arrhythmias; and chest radiography to
compare the cardiothoracic ratio were performed at each
follow-up. Each center had at least 2 doctors who were
specially appointed to perform this work.
The follow-up rate was 100%. The follow-up period
ranged from 3 months to 2 years (14.6  6.2 months).FIGURE 5. Delivery sheath throu
1412 The Journal of Thoracic and Cardiovascular SurPatients took aspirin for 3 months at a dosage of 3 to
5 mg/kg/d. Follow-up was established for each patient.
Seven patients (1.8%) presented with petechiae or pur-
pura and improved after aspirin withdrawal for 3 to 5
days, possibly from aspirin allergy. Nine of the 13 patients
with newly developed trivial or mild tricuspid regurgitation
showed decreased regurgitation. Incomplete right bundle
branch block resolved in 6 of 11 patients, and the other 5 pa-
tients remained stable. There was no new tricuspid regurgi-
tation or arrhythmia detected in the follow-up.
Up to the last follow-up, no residual shunt, new or aggra-
vating aortic regurgitation or tricuspid regurgitation, ob-
struction of left or RV outflow tract, or device dislocation
was detected. There was also no thrombosis or hemolysis.
The lower sternal incisions also caused minimal cosmetic
concern.gh VSD. RV, Right ventricle.
gery c June 2010
FIGURE 6. The left eccentric disk is released, and the right eccentric disk is still in the sheath.
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DDISCUSSION
Compared with conventional open closure and transcath-
eter closure of VSD, the advantages of PVDC of VSD seem
to be obvious. First, this technique eliminates the potential
complications of CPB, with less bleeding, surgical trauma,
and psychologic and cosmetic concern from scar formation.
Second, there is no radiation or femoral arterial injury from
guidewire and sheath insertion when compared with trans-
catheter intervention. Third, the procedure is not constrained
by a patient’s weight and age as in the case of transcatheter
closure. With 3-dimensional stereo imaging, this technique
should be even easier and simpler.
In 1998, Amin and colleagues14 first introduced the prin-
ciple and feasibility of PVDC of VSD in canine models with
special occluder without CPB under the guidance of epicar-
dial echocardiography. Later, Bacha and colleagues4 pub-
lished their experience of PVDC of muscular VSD under
TEE guidance with median sternotomy or subxiphoid mini-FIGURE 7. Completely released device and successful VSD closure with a
The Journal of Thoracic and Carmally invasive incision. However, clinically, PVDC of VSD
has been limited in patients with muscular VSD during the
past 10 years. In 2007, Xing and colleagues6 reported their
first application of PVDC in PMVSDs with a specially mod-
ified delivery system via a 3- to 4-cm subxiphoid incision.
There was no complication reported in their series. Shortly
thereafter, many similar cohorts were reported by other Chi-
nese doctors.7-13
The key point in successfully using this technique is to es-
tablish the correct delivery pathway through the VSD into the
LV cavity. The details of this technique were previously re-
ported by our group.12 In case of closure failure or inappropri-
ate selection of cases for device closure, conventional full
sternotomy should be used to close the VSD under CPB. Con-
version to open surgical repair in this cohort was mainly be-
cause of improper patient selection, and these cases
occurred in the early phase of our learning period. There
was no device failure or other severe complications relatedn eccentric occluder. RV, Right ventricle; LV, left ventricle; AO, aorta.
diovascular Surgery c Volume 139, Number 6 1413
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Dto device closure, such as increased aortic regurgitation, sig-
nificant AVB, and refractory bleeding. Nevertheless, the
real-time TEE monitoring by an experienced cardiologist
and the dexterity of surgeons in handling the device should
be emphasized. According to our experience, the operators
should be familiarwith the technique after 20 to 30 operations.
Aortic insufficiency is a severe complication of VSD
device closure and most commonly occurred. The eccentric
side of the occluder can be easily manipulated to face the
heart apex and thus avoid the risk of aortic regurgitation in
those VSDs that are closer to the aortic valve. The shorter de-
livery pathway and the ease of handling the controllable set
enable the operators to advance the delivery system to the
target defect and accurately deliver the device. In compari-
son, this is relatively more difficult to achieve in transcath-
eter intervention because of the long delivery pathway and
obscure position from an indefinite radiologic angle differ-
ence related to the variation of the VSD position. It may
be an innovation in eccentric occluder deployment that
avoids this complication. In our experience, many VSDs
(45.8%) were close to the aortic valves, but the eccentric oc-
cluders were successfully deployed.
Far from our initial concern, no complete AVB or left bun-
dle branch block occurred in our group compared with the
transcatheter intervention.15-21 As mentioned earlier, PVDC
of PMVSD requires only a short pathway and an easily
controllable set. The guidewire and sheath need to be
advanced less than 5 cm (from the RV free wall to the LV
cavity), vertically crossing the VSD. Therefore, the device
can be deployed in a single try in most circumstances,
without repeating the maneuver. This may be the important
reason why no immediate serious AVBs occurred in our
patients.
Perhaps there were no late AVBs in our patients because
our modified delivery system may reduce ribbing and com-
pressing the tissues near the conductive bundles around the
VSD. Furthermore, the occluders that were used were often
no more than 1 mm, rarely 2 mm larger than the VSD diam-
eter, and almost no oversized occluders have been used.
However, there are no direct data about the mechanisms in-
volved in the occurrence of complete AVB after device clo-
sure of a PMVSD. The current rate of complete AVB after
VSD closure by interventional cardiologists is 1% to
5%.15-20 Predescu and colleagues21 reported an occurrence
rate of 22%, much higher than all other published studies.
However, there were differences in the selection of their pa-
tients from published reports.15-20 Half of their patients were
in our category of contraindications, such as nonrestrictive
VSDs, infants with large VSDs, and severe pulmonary
hypertension. Furthermore, the device deployment
maneuver we used was completely different from theirs. In
addition, only 20 patients were included in their group in
approximately 3 years. We do not know whether the small
number of patients might limit cumulative experience.1414 The Journal of Thoracic and Cardiovascular SurWe have also operated successfully in some patients with
VSD who were turned down by cardiologists for transcath-
eter closure. This may imply the new technique can be used
in a wider patient selection.
Up to the present, we are not able to delineate the defini-
tive indications and contraindications of this technique.
Not all PMVSDs are suitable for PVDC.15-20 According to
our experience, patients with the following conditions are
not suitable for this technique: nonrestrictive VSD, VSD
associated with aortic prolapse, large VSD in neonates or
young children associated with severe pulmonary hyper-
tension, VSD with tricuspid anomaly, and poor echogenic
response. Recently, we have emphasized studying the
outcome of so-called marginal cases. With accumulation
of experience and communication with others, especially
with pioneers such as Drs Amin and Bacha, we may be
able to redefine the indication and contraindications.
With more follow-up data and experience, definitive indi-
cations and contraindications will be achieved.
Clinical Limitations
Although the techniques of PVDC of PMVSD seem to be
safe in the mid-term follow-up, it is not known whether they
are safe in the long term, especially the late complication of
complete AVB and the heart function. More experience and
long-term follow-up are mandatory to assess the actual safety
and effectiveness of this procedure as an alternative to con-
ventional surgery and transcatheter intervention. On the other
hand, the restrictive PMVSDs were those with a diameter be-
tween 3 and 12mm (5.1 2.6 mm). Althoughmore than 400
patients have been successfully treated without serious com-
plications, we do not havemore data to elucidate the exact un-
derlyingmorphologic criteria for size and location of the VSD
suitable for this procedure. This is a new technique for VSD
treatment that is gradually improving. Furthermore, this is
an experience-based and not a laboratory-based summary.
Three-dimensional echocardiography and accumulation of
experience should perfect this technique.
ADDENDUM
The patients in our group have been followed for 6 to 30
months (21.3  5.7 months) with no major complications.
There are now 27 centers in China undertaking this procedure,
with approximately2000patients accepting this new treatment.
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